Trial Profile
A phase II study of imatinib and docetaxel in metastatic hormone refractory prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 28 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 10 Dec 2012 Planned End Date changed from 1 May 2012 to 1 May 2014 as reported by ClinicalTrials.gov.
- 19 Jan 2012 Additional lead trial investigator (Leonard J Appleman) identified as reported by ClinicalTrials.gov.